Pediatr Infect Dis J. 2025 Aug 22. doi: 10.1097/INF.0000000000004920. Online ahead of print.
ABSTRACT
Nirsevimab provides passive immunization against respiratory syncytial virus, yet concerns exist regarding its long-term impact. This study analyzed respiratory syncytial virus-associated lower respiratory tract infection severity in hospitalized children immunized with nirsevimab more than 6 months prior. No significant differences were found compared with nonimmunized children. Findings suggest no increased risk in the following season, supporting nirsevimab’s safety as a preventive strategy.
PMID:40839876 | DOI:10.1097/INF.0000000000004920
